- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06310057
Tofacitinib in the Treatment of Refractory Axial Spondyloarthritis Patients: A Dose Escalation Study
The goal of this clinical trial is to assess the efficacy of tofacitinib in refractory axial spodyloarthritis (ax-SpA) with dose escalation from 10mg to 15mg. Patients will start on 10mg and then divided into 2 groups (10 and 15) at 3rd month according to major improvement criteria.
The main question[s] it aims to answer are:
- Efficacy and safety of tofacitinib in different doses
- If escalation of tofacitinib is justified if clinical criteria is not fulfilled at 10mg
Study Overview
Detailed Description
Axial spondyloarthritis (ax-SpA) is a major cause of chronic low back pain in the young. It causes significant disability and impairs quality of life. Management of (ax-SpA) includes physical therapy along with NSAIDs, followed by TNFi or IL-17i or JAKi in refractory ax-SpA. In Bangladesh, TNFi and IL-17i are expensive, whereas Tofacitinib (JAKi) is affordable and widely used in Bangladesh. However, recent study shows that a significant number of patients, 39.4% do not meet criteria for ASDAS CRP clinically important criteria and only 26% meets the criteria for ASDAS major improvement to tofacitinib 10mg daily. 102 patients of refractory ax-SpA meeting the enrollment criteria will be taken and put on 10mg tofacitinib. Those who fail to attain ASDAS CRP major improvement criteria at 12 weeks will be put on 15mg tofacitinib and both the groups will be compared at week 24 in a dose escalation study.
No studies have been done on 15mg tofacitinib for ax-SpA, such a study will provide us ground for escalation of tofacitinib. Regarding safety issues, FDA has warned against the use of 20mg tofacitinib but not for 15mg. Baseline characteristics and variables will be recorded at initiation of therapy, 4th, 12th and 24th week. The study will take place in Rheumatology outdoor, BSMMU and Modern One Stop Arthritis Care and Research Centre, Dhaka from July 2022- April 2024. Patient's socio-demographic and clinical data will be taken in a semi-structured questionnaire. At every follow up detailed history, thorough physical examination and investigations will be done to evaluate the efficacy and adverse effects. Patients will be assessed for response, ASDAS-CRP, ASDAS-ESR, ASAS-20, BASFI, BASDAI, BASMI, ASQoL, SF-36, MASES and VAS will be noted. CBC, CRP, S. creatinine and S. ALT will be done during follow up.
Study Type
Enrollment (Actual)
Phase
- Phase 4
Contacts and Locations
Study Locations
-
-
-
Dhaka, Bangladesh, 1000
- Bangabandhu Sheikh Mujib Medical University
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Age ≥18 years
- Patient fulfill the ASAS classification criteria for ax-SpA
- Patient fulfill the definition of refractory axial ax-SpA
- Patients with ASDAS-CRP>2.1
Exclusion Criteria:
- Patient currently taking or had prior treatment with bDMARD or tsDMARD (including JAK inhibitor)
- Patient with any active or history of any chronic or recurrent or serious or opportunistic infection/sepsis (including tuberculosis)
- Hemoglobin (Hb) < 9 g/dl
- White blood cell count < 4000, Neutrophil count < 1000, Platelet count < 100000/mm3
- Live vaccines within 3 months prior to the first dose
- GFR less than 50 mL/min
- Alanine aminotransaminase (ALT) more than 2 times of ULN
- Pregnant or breast feeding females of child-bearing potential not using highly effective contraception
- Evidence or history of malignancy
- New York Heart Association Class III and IV congestive heart failure
- Any lymphoproliferative disorder, history of lymphoma, leukemia, or signs and symptoms suggestive of current lymphatic disease
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Tofacitinib 10mg
All patient that fulfill the inclusion ans exclusion criteria will start at 10mg tofacitinib.
|
Tofacitinib (JAKi) is a targeted therapy option for patients with refractory ax-SpA.
|
Experimental: Tofacitinib 15 mg
At 3rd month, patients that do not fulfill the ASDAS major improvement criteria will get 15mg tofacitinib.
|
Tofacitinib (JAKi) is a targeted therapy option for patients with refractory ax-SpA.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
To assess the ASDAS CRP major improvement criteria in refractory ax-SpA patients with dose escalation from 10mg to 15mg
Time Frame: 6 months
|
To assess the ASDAS CRP major improvement criteria in refractory ax-SpA patients with dose escalation from 10mg to 15mg
|
6 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Clinicodemographic characteristics of Ax-SpA, ASDAS CRP outcome rates, quality of life, adverse effects
Time Frame: 6 months
|
|
6 months
|
Collaborators and Investigators
Collaborators
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Infections
- Joint Diseases
- Musculoskeletal Diseases
- Arthritis
- Spinal Diseases
- Bone Diseases
- Spondylarthropathies
- Bone Diseases, Infectious
- Ankylosis
- Spondylitis
- Spondylarthritis
- Axial Spondyloarthritis
- Molecular Mechanisms of Pharmacological Action
- Enzyme Inhibitors
- Protein Kinase Inhibitors
- Janus Kinase Inhibitors
- Tofacitinib
Other Study ID Numbers
- 4139
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Axial Spondyloarthritis
-
UCB Biopharma SRLCompletedNonradiographic Axial SpondyloarthritisUnited States, Belgium, Bulgaria, China, Czechia, France, Germany, Hungary, Japan, Poland, Spain, Turkey, United Kingdom
-
Novartis PharmaceuticalsRecruitingNon-radiographic Axial SpondyloarthritisBelgium, Netherlands, Italy, Thailand, Hungary, Malaysia, Germany, Israel, France, Czechia, Colombia, Romania, Poland, Turkey, Vietnam, Brazil, Mexico, Philippines
-
Sunshine Guojian Pharmaceutical (Shanghai) Co.,...Not yet recruitingAxial SpondyloarthritisChina
-
Merck Sharp & Dohme LLCCompletedSpondyloarthritisCzechia, Germany, Netherlands, Poland, Romania, Russian Federation, Spain, Turkey, Ukraine
-
Novartis PharmaceuticalsActive, not recruitingNon-radiographic Axial SpondyloarthritisChina
-
UCB Biopharma SRLActive, not recruitingAnkylosing Spondylitis | Axial Spondyloarthritis | r-axSpa | Nr-axSpaUnited States, Belgium, Bulgaria, China, Czechia, France, Germany, Hungary, Japan, Netherlands, Poland, Spain, Turkey, United Kingdom
-
Bangabandhu Sheikh Mujib Medical University, Dhaka...Healthcare PharmaceuticalsRecruitingSpondyloarthritis, AxialBangladesh
-
Fondazione Policlinico Universitario Agostino Gemelli...Not yet recruitingSpondyloarthritis | Spondyloarthritis, AxialItaly
-
UCB BIOSCIENCES GmbHCompletedAxial Spondyloarthritis | Nonradiographic Axial Spondyloarthritis | Nr-axSpAUnited States, Australia, Bulgaria, Canada, Czechia, Hungary, Poland, Russian Federation, Taiwan
-
Centre Hospitalier Universitaire de BesanconNot yet recruitingSpondyloarthritis, AxialFrance
Clinical Trials on Tofacitinib
-
PfizerCompletedAnkylosing SpondylitisKorea, Republic of, United States, Spain, Taiwan, Canada, Czech Republic, Poland, Hungary, Germany, Russian Federation
-
PfizerCompleted
-
PfizerCompletedPlaque PsoriasisUnited States
-
PfizerCompleted
-
Nanfang Hospital of Southern Medical UniversityJiangsu Simcere Pharmaceutical Co., Ltd.Not yet recruitingRheumatoid Arthritis
-
PfizerCompleted
-
PfizerCompletedJuvenile Idiopathic ArthritisUnited States, Spain, Turkey, Canada, Australia, Israel, United Kingdom, Argentina, Brazil, Poland, Mexico, Belgium, Russian Federation, Ukraine
-
Stanford UniversityNational Institutes of Health (NIH)RecruitingDiaphragm InjuryUnited States